1191255-15-8
Chemical Structure
Ganomycin I
- CAS No.: 1191255-15-8
- Formula:C21H26O4
- Molecular Weight:342.43
IUPAC Name: (R,E)-5-(2,5-dihydroxyphenyl)-3-(4,8-dimethylnona-3,7-dien-1-yl)furan-2(5H)-one
InChIKey: PXLVYLVZICPHKW-WIRORWGXSA-N
SMILES: OC1=C(C=C(C=C1)O)[C@@]2([H])C=C(C(O2)=O)CC/C=C(C)/CC/C=C(C)/C
Biological Activity: Ganomycin I is a non-competitive dual inhibitor of α-glucosidase and HMG-CoA reductase, with IC50 values of 0.3 μM and 12.3 μM, respectively. Ganomycin I inhibits HIV-1 protease, with an IC50 of 7.5 μg/mL. Ganomycin I also suppresses RANKL-induced osteoclast differentiation and bone resorption by inhibiting the activation of ERK, JNK and p38 MAPK, as well as downregulating the c-Fos/NFATc1 signaling pathway. Ganomycin I exhibits antibacterial activity against Gram-positive bacteria, and shows weak activity against Mycobacterium tuberculosis H37Ra. It can be used in research related to metabolic diseases, bone metabolism and anti-infection[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ganomycin I | Ganomycin I is a non-competitive dual inhibitor of α-glucosidase and HMG-CoA reductase, with IC50 values of 0.3 μM and 12.3 μM, respectively. Ganomycin I inhibits HIV-1 protease, with an IC50 of 7.5 μg/mL. Ganomycin I also suppresses RANKL-induced osteoclast differentiation and bone resorption by inhibiting the activation of ERK, JNK and p38 MAPK, as well as downregulating the c-Fos/NFATc1 signaling pathway. Ganomycin I exhibits antibacterial activity against Gram-positive bacteria, and shows weak activity against Mycobacterium tuberculosis H37Ra. It can be used in research related to metabolic diseases, bone metabolism and anti-infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang K, et al. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. Journal of medicinal chemistry. 2018 Apr 26;61(8):3609-3625. [Content Brief]
- [2]. Tran PT, et al. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2019 Mar 01;55:1-8. [Content Brief]
- [3]. Wang K, et al. A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-Ay mice. Eur J Med Chem. 2017;127:1035-1046.
- [4]. Yajima A, et al. Concise Syntheses and Biological Activities of Ganomycin I and Fornicin A. Eur J Org Chem. 2014:731-738.
- [5]. Chen HP, et al. (+)- and (−)-Ganodilactone, a Pair of Meroterpenoid Dimers with Pancreatic Lipase Inhibitory Activities from the Macromycete Ganoderma leucocontextum. RSC Adv. 2016.
- [6]. Li W, et al. Isolation of 3,4-seco-27-norlanostane triterpenoids from cultivated fruiting bodies of Ganoderma orbiforme. Phytochemistry Letters. 2018;28:104-109.
- [7]. El Dine RS, et al. Inhibition of the dimerization and active site of HIV-1 protease by secondary metabolites from the Vietnamese mushroom Ganoderma colossum. Journal of natural products. 2009 Nov;72(11):2019-23.
